Darejan Ghirdaladze

Statistics

Publications

Citations

439

H-Index

Active since

2008

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Johns Hopkins University

University of Alabama at Birmingham

Darejan Ghirdaladze is an author at The University of Texas MD Anderson Cancer Center specializing in flt3 inhibition, flt3 inhibitors, and tyrosine kinase inhibitors.

Publications per year

2008–2013

Publications

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

Jörge E. Cortes, Hagop M. Kantarjian, James M. Foran et al. · Journal of Clinical Oncology · 2013 · 361 citations · Full text

Medicine, Hematology, Oncology +15

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jörge E. Cortes, James M. Foran, Darejan Ghirdaladze et al. · Blood · 2009 · 66 citations

Medicine, Medicinal Chemistry, Oncology +11

Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor

Jörge E. Cortes, Darejan Ghirdaladze, James M. Foran et al. · Blood · 2008 · 12 citations

Medicine, Oncology, Pharmacology +11

1–3 of 3